CA3055660A1 - Crystalline forms of an androgen receptor modulator - Google Patents

Crystalline forms of an androgen receptor modulator Download PDF

Info

Publication number
CA3055660A1
CA3055660A1 CA3055660A CA3055660A CA3055660A1 CA 3055660 A1 CA3055660 A1 CA 3055660A1 CA 3055660 A CA3055660 A CA 3055660A CA 3055660 A CA3055660 A CA 3055660A CA 3055660 A1 CA3055660 A1 CA 3055660A1
Authority
CA
Canada
Prior art keywords
theta
crystalline form
xrpd
ray powder
powder diffraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3055660A
Other languages
English (en)
French (fr)
Inventor
Nicholas D. Smith
Mark R. Herbert
Ouathek Ouerfelli
Anna Dilhas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Aragon Pharmaceuticals Inc
Original Assignee
Memorial Sloan Kettering Cancer Center
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49712550&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3055660(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Memorial Sloan Kettering Cancer Center, Aragon Pharmaceuticals Inc filed Critical Memorial Sloan Kettering Cancer Center
Priority to CA3114726A priority Critical patent/CA3114726A1/en
Publication of CA3055660A1 publication Critical patent/CA3055660A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA3055660A 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator Abandoned CA3055660A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3114726A CA3114726A1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261656888P 2012-06-07 2012-06-07
US61/656,888 2012-06-07
CA3008345A CA3008345C (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3008345A Division CA3008345C (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3114726A Division CA3114726A1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator

Publications (1)

Publication Number Publication Date
CA3055660A1 true CA3055660A1 (en) 2013-12-12

Family

ID=49712550

Family Applications (4)

Application Number Title Priority Date Filing Date
CA3055660A Abandoned CA3055660A1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator
CA3114726A Pending CA3114726A1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator
CA3008345A Active CA3008345C (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator
CA2875767A Active 2033-07-04 CA2875767C (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator

Family Applications After (3)

Application Number Title Priority Date Filing Date
CA3114726A Pending CA3114726A1 (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator
CA3008345A Active CA3008345C (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator
CA2875767A Active 2033-07-04 CA2875767C (en) 2012-06-07 2013-06-04 Crystalline forms of an androgen receptor modulator

Country Status (45)

Country Link
US (10) US9481663B2 (https=)
EP (4) EP2858985B1 (https=)
JP (3) JP6182209B2 (https=)
KR (2) KR102195916B1 (https=)
CN (3) CN105693692A (https=)
AU (3) AU2013271751B2 (https=)
BR (1) BR112014030678A2 (https=)
CA (4) CA3055660A1 (https=)
CL (1) CL2014003331A1 (https=)
CO (1) CO7240407A2 (https=)
CR (2) CR20190331A (https=)
CY (4) CY1120393T1 (https=)
DK (3) DK3533792T3 (https=)
EA (3) EA201992010A1 (https=)
EC (1) ECSP14030098A (https=)
ES (3) ES2875932T3 (https=)
FR (1) FR21C1050I2 (https=)
GT (1) GT201400283A (https=)
HK (2) HK1210175A1 (https=)
HR (3) HRP20180902T1 (https=)
HU (4) HUE038082T2 (https=)
IL (5) IL320522A (https=)
IN (1) IN2014DN10084A (https=)
LT (4) LT2858985T (https=)
LU (1) LUC00236I2 (https=)
ME (2) ME03815B (https=)
MX (1) MX356754B (https=)
MY (1) MY187500A (https=)
NI (1) NI201400142A (https=)
NL (1) NL301144I2 (https=)
NO (1) NO2021046I1 (https=)
NZ (2) NZ717683A (https=)
PE (3) PE20150631A1 (https=)
PH (2) PH12014502714A1 (https=)
PL (3) PL3533792T3 (https=)
PT (3) PT3348553T (https=)
RS (3) RS60617B1 (https=)
SG (3) SG10201610248SA (https=)
SI (3) SI2858985T1 (https=)
SM (3) SMT201800311T1 (https=)
TR (1) TR201808939T4 (https=)
TW (1) TWI532732B (https=)
UA (2) UA115665C2 (https=)
WO (1) WO2013184681A1 (https=)
ZA (1) ZA201500076B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119015A2 (en) 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
EP2791128A4 (en) 2011-12-16 2015-04-22 Olema Pharmaceuticals Inc NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF
EP2858985B1 (en) 2012-06-07 2018-04-18 Aragon Pharmaceuticals, Inc. Crystalline forms of an androgen receptor modulator
JP6404217B2 (ja) 2012-09-11 2018-10-10 メディベイション プロステイト セラピューティクス エルエルシー エンザルタミドの製剤
NZ744456A (en) 2012-09-26 2019-09-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
PL2945628T3 (pl) * 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
JP2017525727A (ja) * 2014-08-26 2017-09-07 アスター バイオテック リミテッド ライアビリティ カンパニー プロテインキナーゼ阻害剤
HUE054935T2 (hu) * 2014-12-05 2021-10-28 Aragon Pharmaceuticals Inc Rákellenes készítmények
SG11201704267VA (en) 2014-12-05 2017-06-29 Aragon Pharmaceuticals Inc Anticancer compositions
LT3226842T (lt) 2014-12-05 2021-03-25 Aragon Pharmaceuticals, Inc. Priešvėžinės kompozicijos
WO2016100905A1 (en) 2014-12-19 2016-06-23 Lutron Electronics Co., Inc. Multi-channel lighting fixture having multiple light-emitting diode drivers
CA3024872A1 (en) 2016-06-03 2017-12-07 Aragon Pharmaceuticals, Inc. Anticancer compositions
US11149017B2 (en) 2016-12-13 2021-10-19 Watson Laboratories Inc. Solid state forms of apalutamide
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2019135254A1 (en) 2018-01-02 2019-07-11 Mylan Laboratories Limited Apalutamide polymorphs and their preparation thereof
EP3812378A4 (en) * 2018-06-20 2021-04-28 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTALLINE FORMS OF RNA-509, CORRESPONDING METHOD OF PREPARATION AND ASSOCIATED USE
WO2020049598A2 (en) 2018-09-08 2020-03-12 Cipla Limited Apalutamide polymorphs
IT201900003839A1 (it) 2019-03-15 2020-09-15 Olon Spa Sintesi di apalutamide amorfa stabile
WO2020234817A1 (en) * 2019-05-21 2020-11-26 Laurus Labs Limited Polymorphic forms of apalutamide and its preparation thereof
IT201900010593A1 (it) 2019-07-01 2021-01-01 Dipharma Francis Srl Forma cristallina di un inibitore di recettori degli androgeni
US20220281836A1 (en) * 2019-08-22 2022-09-08 Dr. Reddy's Laboratories Limited Process for the preparation of apalutamide
IT201900015974A1 (it) 2019-09-10 2021-03-10 Olon Spa Apalutamide cristallina stabile in forma pura e processo per la sua preparazione
CN110590740A (zh) * 2019-09-20 2019-12-20 武汉大学 一种阿帕鲁胺化合物及其药物制剂
CN116034101B (zh) 2020-09-04 2026-04-03 斯索恩有限公司 制备阿帕鲁胺的改进方法
CN112679468A (zh) * 2021-01-05 2021-04-20 四川科伦药物研究院有限公司 阿帕他胺的晶体形式、制备方法和用途
WO2023143090A1 (zh) * 2022-01-25 2023-08-03 成都苑东生物制药股份有限公司 一种阿帕他胺溶剂化物新晶型及其制备方法
CN115536634B (zh) * 2022-10-17 2024-06-11 上海博悦生物科技有限公司 一种阿帕他胺的合成方法
CN116332907A (zh) * 2023-03-16 2023-06-27 奥锐特药业股份有限公司 一种无定形阿帕他胺的制备方法
WO2025153768A1 (en) * 2024-01-18 2025-07-24 Nanoform Finland Oyj Composition comprising crystalline nanosized apalutamide

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CN101032483B (zh) * 2006-03-09 2011-05-04 陈德桂 调节雄激素受体活性的乙内酰脲衍生物及其应用
SI2656842T1 (sl) * 2006-03-27 2016-10-28 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji
WO2007127010A2 (en) * 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
WO2008119015A2 (en) * 2007-03-27 2008-10-02 Sloan-Kettering Institute For Cancer Research Synthesis of thiohydantoins
AU2011218173C1 (en) * 2010-02-16 2015-04-16 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
EP2858985B1 (en) 2012-06-07 2018-04-18 Aragon Pharmaceuticals, Inc. Crystalline forms of an androgen receptor modulator
EP3812378A4 (en) 2018-06-20 2021-04-28 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTALLINE FORMS OF RNA-509, CORRESPONDING METHOD OF PREPARATION AND ASSOCIATED USE

Also Published As

Publication number Publication date
JP6345821B2 (ja) 2018-06-20
MX2014015005A (es) 2015-09-04
US12018008B2 (en) 2024-06-25
US20190330182A1 (en) 2019-10-31
HRP20180902T1 (hr) 2018-08-24
WO2013184681A1 (en) 2013-12-12
RS57370B1 (sr) 2018-08-31
CL2014003331A1 (es) 2016-03-04
CY1120393T1 (el) 2019-07-10
KR102195916B1 (ko) 2020-12-30
AU2017200298A1 (en) 2017-02-02
FR21C1050I2 (fr) 2024-05-24
LTC3533792I2 (https=) 2024-07-10
US10308630B2 (en) 2019-06-04
MY187500A (en) 2021-09-24
PT3348553T (pt) 2020-09-28
IL267608B1 (en) 2025-06-01
HK1226066A1 (zh) 2017-09-22
US20250092011A1 (en) 2025-03-20
IL236055A0 (en) 2015-02-01
DK2858985T3 (en) 2018-05-28
IL259738B (en) 2021-06-30
EA201791592A1 (ru) 2018-01-31
EP2858985A1 (en) 2015-04-15
ES2809738T3 (es) 2021-03-05
MX356754B (es) 2018-06-11
GT201400283A (es) 2017-07-03
LUC00236I2 (https=) 2025-02-03
SMT202100355T1 (it) 2021-07-12
NI201400142A (es) 2016-12-02
US10934271B2 (en) 2021-03-02
KR20150021993A (ko) 2015-03-03
HUE038082T2 (hu) 2018-09-28
LT2858985T (lt) 2018-09-25
CA3008345C (en) 2019-10-22
KR20190132543A (ko) 2019-11-27
CY1123427T1 (el) 2021-12-31
CR20140549A (es) 2015-04-06
US20170001977A1 (en) 2017-01-05
EP3533792A1 (en) 2019-09-04
CY2021032I2 (el) 2022-03-24
RS61988B1 (sr) 2021-07-30
TW201402561A (zh) 2014-01-16
PH12014502714B1 (en) 2015-02-02
DK3348553T3 (da) 2020-07-27
EP2858985A4 (en) 2016-05-25
CY1124831T1 (el) 2022-03-24
US10766875B2 (en) 2020-09-08
AU2017279807B2 (en) 2018-11-08
SMT201800311T1 (it) 2018-07-17
EA201492272A1 (ru) 2015-05-29
BR112014030678A2 (pt) 2017-06-27
PH12016501470B1 (en) 2021-12-10
SG10201610249TA (en) 2017-02-27
SG11201408140QA (en) 2015-01-29
US20200354335A1 (en) 2020-11-12
NL301144I2 (nl) 2025-03-20
CA2875767A1 (en) 2013-12-12
SI3348553T1 (sl) 2020-11-30
PT2858985T (pt) 2018-07-10
NZ717683A (en) 2018-04-27
EA033956B1 (ru) 2019-12-13
AU2013271751B2 (en) 2017-02-23
EP3533792B1 (en) 2021-05-05
CO7240407A2 (es) 2015-04-17
AU2017279807A1 (en) 2018-01-25
ES2670683T3 (es) 2018-05-31
HUE050357T2 (hu) 2020-11-30
CA3008345A1 (en) 2013-12-12
DK3533792T3 (da) 2021-06-28
PE20150631A1 (es) 2015-05-11
PL3348553T3 (pl) 2021-02-08
JP6182209B2 (ja) 2017-08-16
LTPA2021525I1 (https=) 2021-11-25
IL320522A (en) 2025-06-01
IL259738A (en) 2018-07-31
US20200115361A1 (en) 2020-04-16
IL267608B2 (en) 2025-10-01
ZA201500076B (en) 2016-10-26
EP2858985B1 (en) 2018-04-18
ECSP14030098A (es) 2016-01-29
US20150133481A1 (en) 2015-05-14
PL2858985T3 (pl) 2018-09-28
SG10201610248SA (en) 2017-02-27
ES2875932T3 (es) 2021-11-11
KR102062024B1 (ko) 2020-01-03
SMT202000496T1 (it) 2020-11-10
ME03815B (me) 2021-04-20
LT3348553T (lt) 2020-09-25
CN104619692A (zh) 2015-05-13
EP3348553A1 (en) 2018-07-18
NO2021046I1 (no) 2021-11-02
US20190241539A1 (en) 2019-08-08
US10556882B2 (en) 2020-02-11
AU2013271751A1 (en) 2014-12-18
CN113135892A (zh) 2021-07-20
US20260109683A1 (en) 2026-04-23
EA201992010A1 (ru) 2020-01-24
TR201808939T4 (tr) 2018-07-23
EP3922629A1 (en) 2021-12-15
SI3533792T1 (sl) 2021-11-30
TWI532732B (zh) 2016-05-11
HRP20210909T1 (hr) 2021-09-03
IN2014DN10084A (https=) 2015-08-21
UA123142C2 (uk) 2021-02-24
US10526310B2 (en) 2020-01-07
IL275413A (en) 2020-07-30
PH12014502714A1 (en) 2015-02-02
HRP20201387T1 (hr) 2020-11-27
IL267608A (en) 2019-08-29
CN105693692A (zh) 2016-06-22
CA2875767C (en) 2018-08-14
AU2017200298B2 (en) 2017-09-28
NZ702203A (en) 2016-09-30
PE20200725A1 (es) 2020-07-21
JP2017178923A (ja) 2017-10-05
PH12016501470A1 (en) 2017-07-10
FR21C1050I1 (fr) 2021-12-10
HUS2100047I1 (hu) 2021-11-29
UA115665C2 (uk) 2017-12-11
EA028791B1 (ru) 2017-12-29
JP2018141009A (ja) 2018-09-13
ME03081B (me) 2019-01-20
US9481663B2 (en) 2016-11-01
US20210163441A1 (en) 2021-06-03
PE20200795A1 (es) 2020-08-10
CY2021032I1 (https=) 2022-03-24
JP2015518890A (ja) 2015-07-06
US9994545B2 (en) 2018-06-12
US20180258067A1 (en) 2018-09-13
LT3533792T (lt) 2021-07-26
CA3114726A1 (en) 2013-12-12
CR20190331A (es) 2019-11-12
RS60617B1 (sr) 2020-09-30
PL3533792T3 (pl) 2021-11-29
HUE054595T2 (hu) 2021-09-28
HK1210175A1 (en) 2016-04-15
EP3348553B1 (en) 2020-07-08
SI2858985T1 (sl) 2018-12-31
PT3533792T (pt) 2021-06-07

Similar Documents

Publication Publication Date Title
US20250092011A1 (en) Crystalline Forms Of An Androgen Receptor Modulator
HK40068033A (en) Crystalline forms of an androgen receptor modulator

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190917

FZDE Discontinued

Effective date: 20240116